The present invention relates to the field of medicine, and in particular to a pharmaceutical combination for treating leukemia, comprising an effective dose of chidamide and DCAG drug administered simultaneously, separately or sequentially, the DCAG drug being the combination of decitabine, cytarabine, aclarubicin and granulocyte colony stimulating factor. The invention provides the use of chidamide combined with DCAG in the preparation of a medicament for treating acute myeloid leukemia. Its beneficial effect is solving the relapsed and refractory problem of the existing AML combined chemotherapy regimen. The complete remission rate (CR) in treating patients with acute myeloid leukemia which is relapsed and refractory reached 43.6%, and the objective remission rate (ORR) reached 58.2%.本發明涉及醫藥領域，尤其涉及一種用於治療白血病的聯合用藥物，包括用於同時、分別或依次給藥的具有有效劑量的西達本胺和DCAG藥物，所述DCAG藥物為地西他濱、阿糖胞苷、阿克拉黴素和粒細胞集落刺激因子的組合藥物。本發明提供了西達本胺聯合DCAG在製備用於治療急性髓性白血病的藥物中的用途，其有益效果是：解決了現有AML(acute myelocytic leukemia，急性髓細胞白血病)聯合化療方案的復發難治問題，其治療復發難治的急性髓性白血病患者的完全緩解率(CR，complete response)達到了43.6%，客觀緩解率(ORR，Objective Response Rate)達到了58.2%。
